Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT04241328
Recruiting Observational

Medtronic SYMBIOSIS Post-Market Registry for Patients Undergoing Cardiac Surgery

NCT04241328 · tracked via the Priya Life Science Spain tracker
Sponsor
Medtronic Cardiac Surgery
Phase
Observational
Started
2020-01-09
Last updated
2026-07-30

Condition(s) studied

Cardiovascular Diseases

Study summary

The purpose of this observational, multi-center prospective, post-market registry is to confirm real-world device safety and performance, to ensure the continued acceptability of identified risks, and detect emerging risks.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Subject or legally authorized representative provides written data release and/or informed consent per institution and/or geographical requirements prior to discharge from participating registry hospital. * Subject will undergo or underwent a procedure in which an eligible Medtronic CS product is/was used. Exclusion Criteria: * Currently participating in an interventional drug or device study which may induce confounding factor(s) to the results from this Registry

Primary outcome measure(s)

  • Device Safety — Procedural
    Procedure- , device-related events and device deficiencies
  • Device performance — Procedural
    Device Success

Trial sites (14)

FacilityCityRegionStatus
AKH Wien Vienna Austria Recruiting
Ziekenhuis Oost-Limburg Genk Belgium Completed
UZ Leuven Leuven Belgium Completed
CHU d'Angers Angers France Completed
Clinique Claude Bernard Metz France Terminated
Uniklinik RWTH Aachen Aachen Germany Recruiting
Herz- und Diabeteszentrum NRW Bad Oeynhausen Germany Recruiting
Deutsches Herzzentrum München Munich Germany Recruiting
Onassis Hospital Athens Greece Active Not Recruiting
Catharina Ziekenhuis Eindhoven Netherlands Completed
Maastricht University Medical Center (MUMC+) Maastricht Netherlands Active Not Recruiting
St. Antonius Ziekenhuis Nieuwegein Netherlands Recruiting
Haukeland Universitetssjukehus Bergen Norway Suspended
Hospital Clinic Barcelona Barcelona Spain Completed

More Medtronic Cardiac Surgery trials in Spain

Medtronic Cardiac Surgery PMCF Registry Recruiting

Other trials for the same condition

Effects of Exergaming to Reduce Sedentary Time in Inactive Patients With Heart Failure Recruiting
Real-life Registry in Patients With Coronary Artery Disease Treated With the SELUTION Sirolimus-eluting Balloon. Selution Iberia Registry Recruiting
Pilot Study to Evaluate a Noninvasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With Conduction Disorders Following TAVI Implantation (IMPROVE Study) Recruiting
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk Recruiting
Effectiveness of a Therapeutic Education Program on Female Sexuality in Women Attending Cardiac Rehabilitation. Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04241328 on ClinicalTrials.gov ↗ ← All trials in Spain